Plasma Proteomics to Identify Drug Targets for Ischemic Heart Disease.

"Funding Support and Author Disclosures The CKB baseline survey and the first resurvey were supported by the Kadoorie Charitable Foundation in Hong Kong. The long-term follow-up and subsequent resurveys have been supported by Wellcome grants to Oxford University (212946/Z/18/Z, 202922/Z/16/Z, 104085/Z/14/Z, 088158/Z/09/Z) and grants from the National Natural Science Foundation of China (82192901, 82192904, 82192900) and from the National Key Research and Development Program of China (2016YFC0900500). The UK Medical Research Council (MC_UU_00017/1, MC_UU_12026/2, MC_U137686851), Cancer Research UK (C16077/A29186, C500/A16896), and British Heart Foundation (CH/1996001/9454) provide core funding to the Clinical Trial Service Unit and Epidemiological Studies Unit, Oxford University for the project. The proteomic assays were supported by a BHF Intermediate Clinical Research Fellowship to MVH (FS/18/23/33512), Novo Nordisk, and OLINK. DNA extraction and genotyping were supported by GlaxoSmithKline and the UK Medical Research Council (MC-PC-13049, MC-PC-14135). Dr Holmes is currently employed by 23andMe (and owns stock in 23andMe, Inc). Dr Howson is a full-time employee of Novo Nordisk Research Centre Oxford Limited and owns shares in Novo Nordisk. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose."

"Funding Support and Author Disclosures The CKB baseline survey and the first resurvey were supported by the Kadoorie Charitable Foundation in Hong Kong. The long-term follow-up and subsequent resurveys have been supported by Wellcome grants to Oxford University (212946/Z/18/Z, 202922/Z/16/Z, 104085/Z/14/Z, 088158/Z/09/Z) and grants from the National Natural Science Foundation of China (82192901, 82192904, 82192900) and from the National Key Research and Development Program of China (2016YFC0900500). The UK Medical Research Council (MC_UU_00017/1, MC_UU_12026/2, MC_U137686851), Cancer Research UK (C16077/A29186, C500/A16896), and British Heart Foundation (CH/1996001/9454) provide core funding to the Clinical Trial Service Unit and Epidemiological Studies Unit, Oxford University for the project. The proteomic assays were supported by a BHF Intermediate Clinical Research Fellowship to MVH (FS/18/23/33512), Novo Nordisk, and OLINK. DNA extraction and genotyping were supported by GlaxoSmithKline and the UK Medical Research Council (MC-PC-13049, MC-PC-14135). Dr Holmes is currently employed by 23andMe (and owns stock in 23andMe, Inc). Dr Howson is a full-time employee of Novo Nordisk Research Centre Oxford Limited and owns shares in Novo Nordisk. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose."